Advertising

NASDAQ:ACCD

6.11
0.05 (0.83%) 1d
0
Showing 1 to 1 of 1 entries
  • «
  • 1
  • »
DON'T BUY
It's in personalized healthcare tech; they help employers save on benefits by offering them a single place to get their health and benefit needs. ACCD has a network of nurses, behavioural specialists, and doctors while their platform uses machine learning to give patients correct recommendations which lowers costs and produces better outcomes. For instance, it steers them away from unnecessary emergency room visits and getting their annual physical. ACCD offers a one-stop shop digital health platform. It's barely reaching its total addressable market, now at 5%. ACCD can grow at 40% annually with rising gross margins. The street loves ACCD, boasting 12 buys, all buys. Cathy Wood likes it too, owning 8% as the top shareholder. However, ACCD has been a dog since peaking at $55 last summer. This does not inspire confidence. ACCD went public in July 2020 when IPOs returned; shares jumped at first. Then, it reported super earnings, but then did a secondary offering that hurt stock momentum, then bounced up in December. Last summer, tt reported a weak quarter and shares tumbled to mid-$30s. It's risen a little with last week's tech rally. ACCD has two problems: healthcare has fallen out of fashion in the market, as are stocks without earnings, even if they promise large future earnings. (Remember Teledoc, Amwell or other telemedicine stocks?) ACCD they've bought two companies this year, in primary care and mental health. In May, around the time of these buys, the company lowered their guidance. It trades at a pricey 11x sales, not earnings. In this space, look at GoodRX instead--fast growth and profitable. Also like Doximity and UnitedHealth which just reported a blowout quarter.
Healthcare
Showing 1 to 1 of 1 entries
  • «
  • 1
  • »

Accolade(ACCD-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for Accolade is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Accolade(ACCD-Q) Frequently Asked Questions

What is Accolade stock symbol?

Accolade is a American stock, trading under the symbol ACCD-Q on the NASDAQ (ACCD). It is usually referred to as NASDAQ:ACCD or ACCD-Q

Is Accolade a buy or a sell?

In the last year, 1 stock analyst published opinions about ACCD-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Accolade.

Is Accolade a good investment or a top pick?

Accolade was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Accolade.

Why is Accolade stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Accolade worth watching?

In the last year, there was no coverage of Accolade published on Stockchase.

What is Accolade stock price?

On 2022-05-20, Accolade (ACCD-Q) stock closed at a price of $6.11.